Daptomycin Market Size was valued at USD 3.2 Billion in 2023. The Daptomycin market industry is projected to grow from USD 3.32 Billion in 2024 to USD 4.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.27% during the forecast period (2024 - 2032). Increased skin and skin structure infections, infections in the bloodstream, and right-sided infective endocarditis are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for Daptomycin is being driven by the rising number of people with skin and skin structure infections, its growing use as an antibacterial drug, a bacterial metabolite, and a calcium-dependent antibiotic, rising bloodstream infections like sepsis, the availability of pharmaceuticals, and the prevalence of improved healthcare infrastructure are some of the vital and significant factors that are likely to propel the daptomycin market’s growth in the anticipated period. Bloodstream infections are infective endocarditis, primary bacteremia, central venous catheter-associated bloodstream infections, and those secondary bacteremia owed to focal infections such as osteomyelitis, abscesses, urinary tract infection, or pneumonia. An infectious pathogen spreads the bloodstream by direct invasion into blood vessels via lymphatic vessels, draining a focus of infection such as an abscess or through vascular devices such as needless catheters. Extreme shivering or muscle pain, Slurred speech or confusion, oliguria, respiratory problems, and pale skin with falling blood pressure are all symptoms potentially related to initial sepsis. Bloodstream infections (BSIs) are extremely severe human infections with markedly high morbidity and mortality rates.
Additionally, an increase in R&D activities and the adoption of supportive reimbursement policies will further contribute by creating enormous chances to drive the expansion of the daptomycin market throughout the projected period. For Instance In May 2021, as per clinicaltrials.gov., Ceftobiprole Medocarial under Phase III trials demonstrated an effective treatment option for acute bacterial skin and skin structure infections. The new antibiotic NUZYRA (omadacycline), which comes in oral and intravenous (IV) formulations, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of skin structure infections and community-acquired bacterial pneumonia.
As per Annals of Cardiothoracic Surgery, Right-sided infective endocarditis (RSIE) is less communal than left-sided infective endocarditis (IE), which is only 5% to 10% of cases of IE. Endocarditis affecting the right heart chambers and valves has typical etiologies, epidemiology, and unique diagnostics and therapeutic options. Right-sided infection endocarditis is due to venous drug abuse. Right-sided infective endocarditis associated to drug abuse mostly affects the tricuspid and rarely the pulmonary valves. As per Intech Open, a study in the U.S., North Carolina, reported a 12-fold rise in hospitalizations for intravenous drug use-related IE over the last decade. Right-sided infective endocarditis (RSIE) can be classified into three epidemiological groups intravascular device carriers, intravenous drug users (IDUs), and the ‘three noses’ group, which is no left-sided device or IDUs.
Daptomycin has been used successfully for treating several types of bacterial infections, including acute respiratory tract infection (ARTI), skin & soft tissue infection (SSTI), and bone & joint infection (BJIs) due to its strong and bacterial properties against various microorganisms including methicillin-resistant Staphylococcus aureus (MRSA). This factor, coupled with rising prevalence rates of BJIs across developed countries such as Germany and France, will boost demand over the forecast period. For Instance Thus, driving the Daptomycin market revenue.
The Daptomycin market segmentation, based on indication, includes complicated skin structure infections and bacteremia. The complicated skin structure infections segment dominated the market, accounting for the maximum market revenue. Increased R&D efforts by pharmaceutical and biopharmaceutical companies to develop new products and treatments and expand the prevalence and awareness of skin structure infections contribute to the segment's growth.
The Bacteremia segment is anticipated to be the fastest-growing segment in the projected period. Bacteremia is caused by a bacterial infection in the blood. It can be caused owing to medical procedures and other activities.
The Daptomycin market segmentation, based on age group, includes pediatrics and adults. The adult segment generated the maximum market revenue due to daptomycin used for treating adults suffering from bacteremia and right-sided infective endocarditis. In addition, increasing awareness regarding diseases such as periodontitis and ulcerative colitis among adults is expected to propel growth during the forecast period. For Instance In November 2021, As per a study of Journal of Antimicrobial Chemotherapy, adult patients in National Health Services hospitals in England experience 834,000 hospital-acquired infections (HCAIs) annually, which results in 7.1 million occupied hospital bed days (21% of all annual bed days) and a EUR 2.7 billion (USD 2.8 billion) financial burden.
The Daptomycin market segmentation, based on strength, includes 350mg and 500mg. The 500mg category generated the most income. 500mg is used to cure skin infections and bacterial meningitis. Daptomycin 500mg contains a semi-synthetic antibiotic related to the Polymyxins class by fermenting bacteria genetically modified to produce significant amounts of daptomycin, improving its efficacy and stability.
The 350mg category is anticipated to be the fastest-growing segment in the daptomycin market. It is used to cure complicated skin infections.
Figure 1 Daptomycin Market, by Strength, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Daptomycin market area will dominate this market, owing to increased research & development. In addition, the growing several government initiatives will boost the market growth in this region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 DAPTOMYCIN MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Daptomycin market accounts for the second-largest market share due to the approval of Cubicin medicine by expanding market authorization. Further, the German Daptomycin market held the largest market share, and the UK Daptomycin market was the fastest-growing market in the European region.
The Asia-Pacific Daptomycin Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the rising development of pharmaceutical and healthcare facilities and research. Moreover, China’s Daptomycin market held the largest market share, and the Indian Daptomycin market was the fastest-growing market in the Asia-Pacific region.
Daptomycin Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Daptomycin market, grow even more. Market participants are also undertaking several strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, acquisition and mergers, higher investments, and collaboration with other organizations. The Daptomycin industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Daptomycin industry to benefit clients and increase the market sector. In recent years, the Daptomycin industry has offered some of the most significant advantages to medicine. Major players in the Daptomycin market, including Teva Pharmaceuticals Industries Ltd., Merck & Co., Cipla, Pfizer, BE Pharmaceuticals, Reddy’s Laboratories, Mylan, Fresenius Kabi, Nichi-Iko Pharmaceuticals, Novo Holdings A/S, Zhejiang Hisun, and others, are attempting to increase market demand by investing in research and development operations.
Sandoz is a market leader in generic pharmaceuticals and biosimilars, a part of the Novartis Group. By developing innovative strategies to make high-quality medicine more widely available, Sandoz helps society meet the growing need for healthcare. The company aims to become the world's most prestigious and successful generics firm. Sandoz’s portfolio, comprising about 1000 compounds and covering a wide spectrum of therapeutic areas, is expected to generate $ 9.2 billion in sales by 2022. Sandoz’s extensive selection results in large and recurring savings for patients and payors, ensuring the viability of healthcare systems in the face of severe financial demands and feeling up cash for cutting-edge medications. Every year, the company’s products are used by over 500 million patients. Sandoz’s comprehensive portfolio is driven by its leading positions in generic antibiotics, the cornerstone of international healthcare systems, and biosimilars, the “cutting edge” off-patient medications. The company also carries out several focused corporate responsibility initiatives. For Instance In July 2020, Snadoz released an AP-rated generic version of Cubicin and Daptomycin for injectable 500mg. These injections are used to treat adults with complicated skin and skin structure infections (cSSSI) brought on by Gram-positive bacteria and certain bloodstream infections, such as right-sided infective endocarditis.
Key Companies in the Daptomycin market include
Daptomycin Industry Developments
September 2019 Cipla has introduced daptomycin for injection, a 500mg single dosage, AP-rated generic version of cubic in for an injection. In the US market, the injection treats complex skin conditions.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 3.2 Billion |
| Market Size 2024 | USD 3.32 Billion |
| Market Size 2032 | USD 4.3 Billion |
| Compound Annual Growth Rate (CAGR) | 3.27% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Indication, Age Group, Strength, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Teva Pharmaceuticals Industries Ltd., Merck & Co., Cipla, Pfizer, BE Pharmaceuticals, Reddy’s Laboratories, Mylan, Fresenius Kabi, Nichi-Iko Pharmaceuticals, Novo Holdings A/S, Zhejiang Hisun |
| Key Market Opportunities | Rising use of daptomycin as a bacterial metabolite |
| Key Market Dynamics | Increased infections in the bloodstream, including sepsis Rising demand for daptomycin Growth of right-sided infective endocarditis |
Daptomycin Market Highlights:
Frequently Asked Questions (FAQ) :
The Daptomycin market size was valued at USD 3.2 Billion in 2023.
The market is projected to grow at a CAGR of 3.27% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Teva Pharmaceuticals Industries Ltd., Merck & Co., Cipla, Pfizer, BE Pharmaceuticals, Reddy’s Laboratories, Mylan, Fresenius Kabi, Nichi-Iko Pharmaceuticals, Novo Holdings A/S, Zhejiang Hisun, and others.
The complicated skin structure category dominated the market in 2023.
Adults had the largest share in the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
